Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

VX-147

PreclinicalSmall molecule

Vertex Pharmaceuticals

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Proteinuric Kidney DiseaseRecruiting

Proteinuric Kidney DiseasePreclinical

Recruiting

Timeline

Expected Milestones

Q2 2030

PreclinicalRecruiting

Proteinuric Kidney Disease

NCT05312879

Clinical

Trials by Indication[1]

Focal Segmental Glomerulosclerosis1 trial

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT04340362·16 enrolled

Proteinuric Kidney Disease1 trial

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease

Recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Preclinical·NCT05312879·466 enrolled

Unspecified1 trial

A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 1·NCT05955872·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for VX-147. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VX-147 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VX-147. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vertex Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Vertex Pharmaceuticals

Related News